AstraZeneca: Lymphoma, Large B-Cell, Diffuse trials
The registry lists 12 Lymphoma, Large B-Cell, Diffuse studies with AstraZeneca as lead sponsor. 1 are open to participants now and 4 have results posted.
Phase 1 7Phase 2 4Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLRecruitingNCT05952024Phase 2
- A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal AntibodiesTerminatedNCT02205333Phase 1/2Results posted
- Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell LymphomaCompletedNCT02112526Phase 1Results posted
- Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood CancerCompletedNCT01499303Phase 2Results posted
- A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT01453205Phase 2Results posted
- Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCLCompletedNCT05958134
- A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT04594642Phase 1
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 3
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedNCT03527147Phase 1
- A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological MalignanciesCompletedNCT03106428Phase 1
- AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT02780830Phase 1
- MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)CompletedNCT02549651Phase 1